摘要
目的观察多西他赛联合卡铂(DC)治疗复发或转移性乳腺癌的效果和安全性。方法68例复发或转移性乳腺癌患者被随机分为DC组(33例)和对照组(35例)。DC组采用多西他赛联合卡铂治疗,对照组采用长春瑞滨(NVB)联合顺铂(DDP)组成NP方案治疗,评价两组的近远期疗效,观察不良反应。结果DC组有效率为46.9%,疾病控制率71.9%;对照组有效率为41.9%,疾病控制率68.8%。两组近期疗效差异无统计学意义(P>0.05)。DC组患者生存率为28.1%,死亡率为71.9%;对照组生存率为22.6%,死亡率为77.4%,两组远期疗效比较差异无统计学意义(P>0.05)。两组均出现严重的白细胞减少和脱发现象,发生率>90%,但DC组Ⅲ～Ⅳ级毒副作用发生率显著低于对照组(P<0.05);DC组出现关节肌肉痛、恶心呕吐和静脉炎的发生率和Ⅲ～Ⅳ级毒副作用发生率均显著低于对照组(P<0.05)。结论多西他赛联合卡铂治疗复发或转移性乳腺癌疗效确切,不良反应可以耐受,值得临床进一步开展研究和推广。
Objective To explore the clinical effectiveness and safety of docetaxel combined with carboplatin （DC） in treating recurrent or metastatic breast cancer. Methods Totally 68 Patients with recurrent or metastatic breast cancer were randomly divided into DC group and control group. DC group was given docetaxel combined with carboplatin, while the contol group was given NVB combined with DDP. The clinical effectiveness and safety were evaluated. Results In DC group, the response rate was 46. 9% and disease control rate of 71.9%; in the control group, the response rate was 41.9% and disease control rate was 68.8% （P 〉 0. 05）. In the DC group, the survival rate was 28. 1% and the mortality rate was 71.9% ; in the control group, the survival rate was 22. 6% and the mortality rate was 77.4% （P 〉 0. 05）. Severe leukopenia and hair loss was noted in both two groups （ 〉 90% ）. However, in the DC group, Ⅲ-Ⅳ level toxic events were significantly less than in the control group （P 〈 0. 05） ; also, grade Ⅲ-Ⅳ incidences of joint muscle pain, nausea and vomiting were significantly lower than in the control group （P 〈 0. 05）. Conclusion Docetaxel combined with carboplatin is effective in treatment of recurrent or metastatic breast cancer, and its adverse reactions are acceptable.
出处
《癌症进展》
2009年第6期657-661,共5页
Oncology Progress
关键词
乳腺癌
复发转移
多西他赛
卡铂
breast cancer recurrent or metastatic docetaxel carboplatin
